As the sponsor of the Keynote Oncology Clinical Trials, Merck is passionate about improving health. We are committed to accelerating every step in the journey in our quest to bring treatment options to people with cancer.
Pembrolizumab has been FDA-approved for use in certain types of cancer.
To see if your patients qualify for one of these trials, contact our clinical trial information center at 1-888-577-8839. If you are interested in partnering with us as an investigator, call 1-800-290-4339.
|Trial Description||Keynote Trial||Condition||Phase||Status|
|Study of Pembrolizumab as Monotherapy in Participants With Advanced Hepatocellular Carcinoma||224||Hepatocellular Carcinoma||Phase 2||Active, not recruiting|
|Study of Pembrolizumab vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma||240||Hepatocellular Carcinoma||Phase 3||Active, not recruiting|